Tokyo-based Alpha Fusion and Chester Springs, PA-based Curadh MTR plan to enter a strategic partnership focused on global development of astatine-211 (At-211)-based radiopharmaceuticals.
The collaboration combines Alpha Fusion's role in At-211 drug discovery and early clinical work in Japan with Curadh MTR's global expertise in radiopharmaceutical development. The joint venture will focus on clinical development of lead products in the U.S. as well as broadly developing a pipeline of At-211 products, Alpha Fusion said.
The companies announced their plans at the World Astatine Community meeting held June 19 to 20 in New Orleans, LA, Alpha Fusion noted.
